<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38807038</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine.</ArticleTitle><Pagination><StartPage>535</StartPage><MedlinePgn>535</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">535</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09389-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To assess the immunogenicity of the current primary polio vaccination schedule in China and compare it with alternative schedules using Sabin or Salk-strain IPV (sIPV, wIPV).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cross-sectional investigation was conducted at four sites in Chongqing, China, healthy infants aged 60-89 days were conveniently recruited and divided into four groups according to their received primary polio vaccination schedules (2sIPV + bOPV, 2wIPV + bOPV, 3sIPV, and 3wIPV). The sero-protection and neutralizing antibody titers against poliovirus serotypes (type 1, 2, and 3) were compared after the last dose.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 408 infants completed the protocol. The observed seropositivity was more than 96% against poliovirus types 1, 2, and 3 in all groups. IPV-only groups induced higher antibody titers(GMT) against poliovirus type 2 (Median:192, QR: 96-384, P&lt;0.05) than the "2IPV + bOPV" group. While the "2IPV + bOPV" group induced significantly higher antibody titers against poliovirus type 1 (Median:2048, QR: 768-2048, P&lt;0.05)and type 3 (Median:2048, QR: 512-2048, P&lt;0.05) than the IPV-only group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings have proved that the two doses of IPV with one dose of bOPV is currently the best polio routine immunization schedule in China.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xu</LastName><ForeName>Jiawei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>EPI Department, Chongqing Municipal Center for Disease Control and Prevention, No.8 Changjiang 2nd Street, Yuzhong District, Chongqing, 400042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>EPI Department, Chongqing Municipal Center for Disease Control and Prevention, No.8 Changjiang 2nd Street, Yuzhong District, Chongqing, 400042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>EPI Department, Chongqing Municipal Center for Disease Control and Prevention, No.8 Changjiang 2nd Street, Yuzhong District, Chongqing, 400042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wenwen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>EPI Department, Hechuan District Center Disease Control and Prevention, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiaoxiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>EPI Department, Liangping District Center Disease Control and Prevention, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>EPI Department, Rongchang District Center Disease Control and Prevention, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>EPI Department, Zhongxian County Center Disease Control and Prevention, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Wenge</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>EPI Department, Chongqing Municipal Center for Disease Control and Prevention, No.8 Changjiang 2nd Street, Yuzhong District, Chongqing, 400042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yujie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health, Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>EPI Department, Chongqing Municipal Center for Disease Control and Prevention, No.8 Changjiang 2nd Street, Yuzhong District, Chongqing, 400042, China. 576801380@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>EPI Department, Chongqing Municipal Center for Disease Control and Prevention, No.8 Changjiang 2nd Street, Yuzhong District, Chongqing, 400042, China. yaoningaa@outlook.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Statistics, College of Preventive Medicine, Army Medical University, Chongqing, 400038, China. yaoningaa@outlook.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2020FYYX040</GrantID><Agency>Chongqing Health Commission and Chongqing Science and Technology Commission</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="Y">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IPV</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Sequential immunization</Keyword><Keyword MajorTopicYN="N">bOPV</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>29</Day><Hour>0</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>28</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38807038</ArticleId><ArticleId IdType="pmc">PMC11131326</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09389-8</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09389-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Estivariz CF et al. Chapter 18: Poliomyelitis. Epidemiology and prevention of vaccine-preventable diseases, a.k.a. The Pink Book[M]. 14. Centers for Disease Control and Prevention, United States of America, 2021.</Citation></Reference><Reference><Citation>WHO. Poliomyelitis (polio)[EB/OL]. https://www.who.int/health-topics/poliomyelitis#tab=tab_1.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Polio Eradication and Endgame Strategic Plan 2013–2018[EB/OL]. https://polioeradication.org/who-we-are/strategic-plan-2013-2018/.</Citation></Reference><Reference><Citation>Agency Of Disease Control And Prevention. Vaccination work specifications[EB/OL]. (2016-12-29)http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=8033406a995d460f894cb4c0331cb400.</Citation></Reference><Reference><Citation>WHO Polio vaccines: WHO position paper – June 2022[J] Wkly Epidemiol Rec. 2022;25(97):277–300.</Citation></Reference><Reference><Citation>Macklin GR, O’Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine[J] Science. 2020;368(6489):401–5. doi: 10.1126/science.aba1238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba1238</ArticleId><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper LV, Bandyopadhyay AS, Gumede N, et al. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa[J] Lancet Infect Dis. 2022;22(2):284–94. doi: 10.1016/S1473-3099(21)00453-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00453-9</ArticleId><ArticleId IdType="pmc">PMC8799632</ArticleId><ArticleId IdType="pubmed">34648733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wilkinson A, et al. Updated characterization of outbreak response strategies for 2019–2029: impacts of using a novel type 2 oral Poliovirus Vaccine Strain[J] Risk Anal. 2021;41(2):329–48. doi: 10.1111/risa.13622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13622</ArticleId><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake IM, Pons-Salort M, Molodecky NA, et al. Type 2 Poliovirus Detection after global withdrawal of trivalent oral Vaccine[J] N Engl J Med. 2018;379(9):834–45. doi: 10.1056/NEJMoa1716677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1716677</ArticleId><ArticleId IdType="pmc">PMC5985919</ArticleId><ArticleId IdType="pubmed">30157398</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleem AF, Yousafzai MT, Mach O, et al. Evaluation of vaccine derived poliovirus type 2 outbreak response options: a randomized controlled trial, Karachi, Pakistan[J] Vaccine. 2018;36(13):1766–71. doi: 10.1016/j.vaccine.2018.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.02.051</ArticleId><ArticleId IdType="pmc">PMC5869272</ArticleId><ArticleId IdType="pubmed">29477307</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, Jorba J, Greene SA, et al. Update on vaccine-derived Poliovirus outbreaks - Worldwide, July 2019-February 2020[J] MMWR Morb Mortal Wkly Rep. 2020;69(16):489–95. doi: 10.15585/mmwr.mm6916a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6916a1</ArticleId><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigouette JP, Henderson E, Mohamed A, Traoré, et al. Update on vaccine-derived Poliovirus outbreaks - Worldwide, January 2021-December 2022[J] MMWR Morb Mortal Wkly Rep. 2023;72(14):366–71. doi: 10.15585/mmwr.mm7214a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7214a3</ArticleId><ArticleId IdType="pmc">PMC10078846</ArticleId><ArticleId IdType="pubmed">37022974</ArticleId></ArticleIdList></Reference><Reference><Citation>Stehling-Ariza T, Wilkinson AL, Diop OM, et al. Surveillance to Track Progress toward Poliomyelitis Eradication-Worldwide, 2021–2022. Morb Mortal Wkly Rep. 2023;72(23):613–20. doi: 10.15585/mmwr.mm7223a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7223a1</ArticleId><ArticleId IdType="pmc">PMC10328463</ArticleId><ArticleId IdType="pubmed">37289657</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Qiang Q, Yuhua L, Hongying, et al. Compare the polio antibody level before and after the conversion of inactivated poliovirus vaccine immunization program[J] Chin J Microbiol Immunol. 2021;41(07):550–4.</Citation></Reference><Reference><Citation>Yang Xiuhui Z, Yong Z, Shuangli, et al. To evaluate the neutralizing antibody of poliovirus in children aged &lt; 12 years of Fujian Province[J] Chin J Experimental Clin Virol. 2021;35(05):548–54.</Citation></Reference><Reference><Citation>Wang Qing Z, Yuanyuan X. Immunogenicity of sequential polio vaccination schedules that use inactivated polio vaccine as the first dose[J] Chin J Vaccines Immun. 2019;25(04):378–82.</Citation></Reference><Reference><Citation>Wen Ning S, Qiru A, Zhijie, et al. Considerations and suggestions for polio vaccination strategies in China[J] Chin J Vaccines Immunizations. 2018;24(03):349–53.</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of Poliovirus Antibodies[J] Methods Mol Biol. 2016;1387:145–76. doi: 10.1007/978-1-4939-3292-4_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3292-4_8</ArticleId><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent DC, I, Merchant AT, Fisher-Hoch S, et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules[J] Vaccine. 2003;21(15):1710–8. doi: 10.1016/S0264-410X(02)00523-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00523-6</ArticleId><ArticleId IdType="pubmed">12639494</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine[J] N Engl J Med. 2013;368(5):416–24. doi: 10.1056/NEJMoa1202541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202541</ArticleId><ArticleId IdType="pubmed">23363495</ArticleId></ArticleIdList></Reference><Reference><Citation>Geneva: World Health Organization. Considerations for the timing of a single dose of IPV in the routine immunization schedule[EB/OL]. (2014-06-03)https://www.who.int/publications/i/item/WER8901.</Citation></Reference><Reference><Citation>Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of Poliomyelitis in the United States[J] JAMA. 2004;292(14):1696–701. doi: 10.1001/jama.292.14.1696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.292.14.1696</ArticleId><ArticleId IdType="pubmed">15479934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India[J] Science. 2014;345(6199):922–5. doi: 10.1126/science.1255006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1255006</ArticleId><ArticleId IdType="pmc">PMC10389671</ArticleId><ArticleId IdType="pubmed">25146288</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaensbauer JT, Gast C, Bandyopadhyay AS, et al. Impact of maternal antibody on the immunogenicity of inactivated Polio Vaccine in infants immunized with bivalent oral Polio Vaccine: implications for the Polio Eradication Endgame[J] Clin Infect Dis. 2018;67(suppl1):S57–65. doi: 10.1093/cid/ciy649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy649</ArticleId><ArticleId IdType="pmc">PMC6206111</ArticleId><ArticleId IdType="pubmed">30376095</ArticleId></ArticleIdList></Reference><Reference><Citation>Asturias EJ, Bandyopadhyay AS, Self S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in latin American infants: an open-label randomised controlled trial[J] Lancet. 2016;388(10040):158–69. doi: 10.1016/S0140-6736(16)00703-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00703-0</ArticleId><ArticleId IdType="pubmed">27212429</ArticleId></ArticleIdList></Reference><Reference><Citation>Li-na GENG, Kai CHU, Guang-wei SUN, et al. Effectiveness of OPV and the influence of maternal anti-poliovirus antibodies on evaluation of OPV in the Chinese infants[J] Mod Prev Med. 2017;44(08):1503–6.</Citation></Reference><Reference><Citation>Min CUI, De-yu JIANG, Qing HE. Changes in poliovirus neutralizing antibodies among puerperas and infants: a longitudinal study[J] Chin J Public Health. 2016;32(07):889–92.</Citation></Reference><Reference><Citation>Albrecht P, Enterline JC, Boone EJ, et al. Poliovirus and Polio antibody assay in HEp-2 and Vero cell cultures[J] J Biol Stand. 1983;11(2):91–7. doi: 10.1016/S0092-1157(83)80031-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-1157(83)80031-6</ArticleId><ArticleId IdType="pubmed">6306012</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Wang Q, Kuang S, et al. Immunogenicity of sequential poliovirus vaccination schedules with different strains of Poliomyelitis vaccines in Chongqing, China: a cross-sectional survey[J] Hum Vaccin Immunother. 2021;17(7):2125–31. doi: 10.1080/21645515.2020.1868269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1868269</ArticleId><ArticleId IdType="pmc">PMC8189127</ArticleId><ArticleId IdType="pubmed">33759702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>